当前位置: 首页 >> 检索结果
341. Epidemiology of Coronary Atherosclerosis Among People Living With HIV in Uganda : A Cross-Sectional Study.
作者: Mark J Siedner.;Brian Ghoshhajra.;Geoffrey Erem.;Rita Nassanga.;Mangun Randhawa.;Andrew Ochieng.;Moses Acan.;Michael T Lu.;Vikas Thondapu.;Angelo Takigami.;Zahra Reynolds.;Flavia Atwiine.;Edna Tindimwebwa.;Rebecca F Gilbert.;Eliza Passell.;Shruti Sagar.;Yao Tong.;Ntobeko A B Ntusi.;Alexander C Tsai.;Prossy Bibangambah.;Thomas Gaziano.;Susanne S Hoeppner.;Christopher T Longenecker.;Samson Okello.;Stephen Asiimwe.
来源: Ann Intern Med. 2025年178卷4期468-478页
Data on the prevalence of coronary atherosclerotic disease (CAD) in the African region among people with and without HIV are lacking.
342. Health Care Delivery of Clinical Preventive Services for People With Disabilities : A Systematic Review.
作者: David I Buckley.;Frances Hsu.;Tracy Dana.;Keeley Blackie.;Rebecca Holmes.;Peggy Nygren.;Willi Horner-Johnson.;Christina Nicolaidis.;Roger Chou.
来源: Ann Intern Med. 2025年178卷5期671-686页
People with disabilities are less likely than the general population to receive clinical preventive services.
343. Gout.
Gout is characterized by deposition of monosodium urate (MSU) crystals in or around joints, tendons, bursae, and other tissues, resulting in painful recurrent flares and tissue damage. Gout is the most common form of inflammatory arthritis, with a prevalence of 5.1% in the United States, affecting 12.1 million adults. When urate levels exceed the limit of solubility (6.8 mg/dL [400 μmol/L]), MSU crystals may form or grow. Gout flares are the result of inflammatory responses to MSU crystals. The primary method to prevent and reduce gout flares, tophi, chronic inflammatory arthritis, and joint damage is to reduce urate levels below the saturation threshold. The pathophysiology of gout is well understood, and inexpensive and effective therapies are available. However, outcomes for patients with gout remain poorly optimized.
344. Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline.
作者: Magdalena Madero.;Adeera Levin.;Sofia B Ahmed.;Juan Jesus Carrero.;Bethany Foster.;Anna Francis.;Rasheeda K Hall.;William G Herrington.;Guy Hill.;Lesley A Inker.;Rümeyza Kazancıoğlu.;Edmund Lamb.;Peter Lin.;Natasha McIntyre.;Kelly Morrow.;Glenda Roberts.;Dharshana Sabanayagam.;Michael Shlipak.;Rukshana Shroff.;Navdeep Tangri.;Teerawat Thanachayanont.;Ifeoma Ulasi.;Germaine Wong.;Chih-Wei Yang.;Luxia Zhang.;Karen A Robinson.;Lisa M Wilson.;Renee F Wilson.;Bertram L Kasiske.;Michael Cheung.;Amy Earley.;Paul E Stevens.;Elke Schaeffner.
来源: Ann Intern Med. 2025年178卷5期705-713页
The Kidney Disease: Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 to provide guidance on the evaluation, management, and treatment of chronic kidney disease (CKD) in adults and children who are not receiving kidney replacement therapy.
346. In previous MI with ventricular tachycardia (VT), catheter ablation reduced mortality or VT events more than antiarrhythmic drug therapy at 4 y.
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].
347. In symptomatic severe tricuspid regurgitation, adding TTVR to medical therapy improved a hierarchical composite outcome at 1 y.
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].
350. Molecular Imaging Versus Adrenal Vein Sampling for the Detection of Surgically Curable Primary Aldosteronism : A Prospective Within-Patient Trial.
作者: Emily Goodchild.;Xilin Wu.;Russell Senanayake.;James MacFarlane.;Giulia Argentesi.;Kate Laycock.;Waiel A Bashari.;Claudia P Cabrera.;Samuel M O'Toole.;Jackie Salsbury.;Daniela Benu.;Yun-Ni Lee.;Aldons C N Chua.;Matthew Matson.;Brendan Koo.;Laila Parvanta.;Nicholas Hilliard.;Vasilis Kosmoliaptsis.;Alison Marker.;Daniel M Berney.;Kiera Drew.;Wilson Tan.;Roger Foo.;Charles A Mein.;Eva Wozniak.;Jessica Kearney.;Emanuel Savage.;Anju Sahdev.;Nicholas Bird.;Graham Smith.;Matthew Hird.;Victoria Warnes.;Daniel Gillett.;Anne Dawnay.;Elizabeth Adeyeye.;Franklin Aigbirhio.;Alasdair McIntosh.;Alex McConnachie.;J Kennedy Cruickshank.;Heok Cheow.;Mark Gurnell.;William M Drake.;Morris J Brown.
来源: Ann Intern Med. 2025年178卷3期336-347页
Primary aldosteronism (PA) causes hypertension and is potentially surgically curable when it is caused by a unilateral aldosterone-producing adrenal adenoma (APA). Adrenal vein sampling (AVS) is required to guide surgery, but it is invasive, is technically difficult, and has limited availability.
354. In acute MI and acute or chronic anemia, liberal vs. restrictive transfusion did not affect recurrent MI or death.
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Hematology: [Formula: see text].
355. In hospitalized patients with BSI, antibiotic therapy for 7 d was noninferior to 14 d for 90-d mortality.
GIM/FP/GP: [Formula: see text] Infectious Disease: [Formula: see text] Critical Care: [Formula: see text].
356. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression in Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
作者: Huilin Tang.;Ying Lu.;William T Donahoo.;Sarah C Westen.;Yong Chen.;Jiang Bian.;Jingchuan Guo.
来源: Ann Intern Med. 2025年178卷3期315-326页
Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown potential antidepressant effects, population studies yield inconsistent results.
357. Development of Prompt Templates for Large Language Model-Driven Screening in Systematic Reviews.
作者: Christian Cao.;Jason Sang.;Rohit Arora.;David Chen.;Robert Kloosterman.;Matthew Cecere.;Jaswanth Gorla.;Richard Saleh.;Ian Drennan.;Bijan Teja.;Michael Fehlings.;Paul Ronksley.;Alexander A Leung.;Dany E Weisz.;Harriet Ware.;Mairead Whelan.;David B Emerson.;Rahul K Arora.;Niklas Bobrovitz.
来源: Ann Intern Med. 2025年178卷3期389-401页
Systematic reviews (SRs) are hindered by the initial rigorous article screen, which delays access to reliable information synthesis.
358. Prevalence of Chronic Medical Conditions Among Medicare Advantage and Traditional Medicare Beneficiaries.
作者: Andrew S Oseran.;Rahul Aggarwal.;Jose Figueroa.;Karen E Joynt Maddox.;Bruce E Landon.;Rishi K Wadhera.
来源: Ann Intern Med. 2025年178卷3期327-335页
The federal government spends billions of dollars per year on payments to Medicare Advantage (MA) plans based, in part, on beneficiaries' risk scores. Despite this, little is known about the true burden of chronic medical conditions among MA beneficiaries compared with those in fee-for-service (FFS) Medicare.
359. De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome : A Systematic Review and Individual Patient Data Meta-analysis of Randomized Clinical Trials.
作者: Yong-Joon Lee.;Xiaofei Gao.;Sang-Hyup Lee.;Jing Kan.;Jun-Jie Zhang.;Seung-Jun Lee.;Sung-Jin Hong.;Chul-Min Ahn.;Jung-Sun Kim.;Byeong-Keuk Kim.;Young-Guk Ko.;Donghoon Choi.;Yangsoo Jang.;Gregg W Stone.;Shao-Liang Chen.;Myeong-Ki Hong.
来源: Ann Intern Med. 2025年178卷4期533-542页
The role of transitioning from short dual antiplatelet therapy (DAPT) to potent P2Y12 inhibitor monotherapy in patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation remains inconclusive.
360. The Target Trial Framework for Causal Inference From Observational Data: Why and When Is It Helpful?
作者: Miguel A Hernán.;Issa J Dahabreh.;Barbra A Dickerman.;Sonja A Swanson.
来源: Ann Intern Med. 2025年178卷3期402-407页
When randomized trials are not available to answer a causal question about the comparative effectiveness or safety of interventions, causal inferences are drawn using observational data. A helpful 2-step framework for causal inference from observational data is 1) specifying the protocol of the hypothetical randomized pragmatic trial that would answer the causal question of interest (the target trial), and 2) using the observational data to attempt to emulate that trial. The target trial framework can improve the quality of observational analyses by preventing some common biases. In this article, we discuss the utility and scope of applications of the framework. We clarify that target trial emulation resolves problems related to incorrect design but not those related to data limitations. We also describe some settings in which adopting this approach is advantageous to generate effect estimates that can close the gaps that randomized trials have not filled. In these settings, the target trial framework helps reduce the ambiguity of causal questions.
|